Neurocysticercosis, caused by Taenia solium, presents with a spectrum of disease. 1 The most common presentation in patients diagnosed in India and the United States is with seizures and/or headaches and a single enhancing lesion. Patients with this presentation have a good prognosis. In Latin America, most patients come to medical attention with multiple cystic lesions and recurrent seizures. Both of these groups seem to do well when treated with antiepileptic drugs, steroids, and antiparasitic drugs. Patients with multiple parenchymal cysts may benefit from combination therapy with albendazole and praziquantel. 2 In endemic villages, populationbased surveys note that it is more common to have calcified lesions from prior cystic lesions. [3] [4] [5] Many cases are asymptomatic, but patients may also have chronic epilepsy. A minority of patients present with extra-parenchymal disease with cysticerci in the ventricles causing obstructive hydrocephalus or with subarachnoid disease associated with arachnoiditis. 6 The latter are associated with a particularly poor prognosis.
In 1987, Sotelo and Marin 7 published a pivotal article describing the natural history of 92 patients with hydrocephalus due to subarachnoid neurocysticercosis. All of them underwent shunt placement to ameliorate hydrocephalus. Despite surgical intervention, the prognosis remained poor: 34 died within 2 years and only half survived to the last followup (median 8 years). Most of the survivors had continued arachnoiditis. In contrast to that report and some more recent reports, 8 Nash and others 9 report no fatalities with subarachnoid neurocysticercosis from a series of 30 patients followed at the NIH in the United States. Other series have also noted few fatalities with optimal management. 10, 11 Why has there been such a stark difference in case fatality rates between studies? The main difference in the management of patients between the older series and more recent reports is the recent aggressive use of antiparasitic and anti-inflammatory drugs and aggressive management of increased intracranial pressure.
The role of antiparasitic drugs in neurocysticercosis has been controversial. Early on Sotelo and others noted favorable responses when patients with parenchymal neurocysticercosis were treated with antiparasitic drugs. 12, 13 However, the initial studies were not optimally controlled, and the first randomized trial suggested no benefit. 14 Subsequent well-designed, double-blind, randomized trials demonstrated that antiparasitic drugs for cystic parenchymal lesions clearly hastened cyst resolution and led to fewer generalized seizures. 15, 16 The effect was more limited for patients with single enhancing lesions, but meta-analyses continue to demonstrate that treatment with albendazole plus corticosteroids led to more rapid radiographic resolution and fewer seizures in the short term. 17 The role of antiparasitic drugs in extra-parenchymal disease has been even more controversial. For example, Agapejev documented a 36% fatality rate with albendazole treatment. 18 By contrast, Proaño and others 19 noted that although patients with giant cysticerci (who mostly had subarachnoid neurocysticercosis) responded poorly to single courses of antiparasitic drugs, most had a good prognosis when treated with repeated courses. Nash and others 9 took a different approach. Instead, patients were treated with prolonged courses of antiparasitic drugs, typically lasting 6-12 months. This was associated with resolution in all but one case, and that case was still on treatment at the time of writing. Some were treated with a combination of praziquantel and albendazole. Combination therapy could potentially kill parasites more rapidly, and further studies of this approach are needed. Other investigators have used high-dose albendazole in short cycles, repeated as needed, with results similar to those noted by Nash. 6, 10 Clearly, host inflammation plays a key role in the pathogenesis of neurocysticercosis. Nash and others 9 also used an aggressive approach to anti-inflammatory therapy. Most of the patients received high doses of corticosteroids for over a year. To continue anti-inflammatory therapy in the presence of or in anticipation of steroid-related adverse events, most of the patients were also treated with methotrexate and/or etanercept. 9, 20 However, there was significant variability in regimens between patients. Thus, although anti-inflammatory therapy appears to be critically important, more studies are needed on optimal agents, doses, and duration and on how to individualize therapy.
A third aspect of this case series is the use of neurosurgery. Fourteen patients (41%) required placement of a ventriculoperitoneal shunt and one underwent third ventriculostomy. 9 Although shunt failure was noted, it was less frequent than in older series. This may have been due to the use of antiparasitic drugs and/or anti-inflammatory treatment, which were associated with improved shunt survival in other series. 21, 22 Others have proposed debulking via minimally invasive neurosurgery. 23 This was not performed in the series by Nash and others and remains an experimental approach.
If patients are treated with prolonged or repeated courses of antiparasitic drugs, how long should the treatment be continued and what are the end points? Resolution by neuroimaging does not seem to correlate well with long-term response. For example, Nash and others noted three patients who relapsed after apparent radiologic resolution. 9 In other cases, scarring may lead to an incomplete radiologic response even in the setting of elimination of viable parasites. Nash and others now propose using monoclonal antibody-based, antigen-capture ELISA assays as a way of following the therapeutic response. This has previously been demonstrated to better correlate with the response to therapy than does follow-up imaging. 24 However, there is currently limited availability of antigen detection assays in the United States. More recently, a real time PCR assay has been proposed for use in the follow-up of patients with subarachnoid neurocysticercosis. 25 Clearly, further studies are needed to determine optimal duration of therapy and clinical end points.
Neurocysticercosis represents a spectrum of disease with variable clinical presentation and optimal management. In all forms of disease, symptomatic therapy is critically important, including aggressive management of elevated intracranial pressure. Antiparasitic drugs, anti-inflammatory drugs, and neurosurgery all play a key role in management. For subarachnoid neurocysticercosis, the data from Nash and others suggest that aggressive therapy with prolonged courses or high doses of antiparasitic and anti-inflammatory therapy is beneficial. 1 They also suggest that individualization of management based on antigen detection and inflammatory markers should improve prognoses. Even with this aggressive approach, most patients had at least some neurologic sequelae. Clearly, additional studies are needed to determine optimal antiparasitic and anti-inflammatory therapy for this severe form of disease.
